Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 332 articles:
HTML format



Single Articles


    August 2024
  1. GANESH A, Galetta SL
    Editors' Note: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2024;103:e209634.
    PubMed    


  2. CONNOLLY E, O'Connor A, Fallon A, O'Dowd S, et al
    Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2024;103:e209343.
    PubMed    


  3. VASSILAKI M, Graff-Radford J
    Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2024;103:e209371.
    PubMed    


  4. HOLPER S, Loveland P, Churilov L, Italiano D, et al
    Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis.
    Neurology. 2024;103:e209537.
    PubMed     Abstract available


    July 2024
  5. HAMILTON CA, Donaghy PC, Durcan R, Ciafone J, et al
    Outcomes of Patients With Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease at 3 and 5 Years After Diagnosis.
    Neurology. 2024;103:e209499.
    PubMed     Abstract available


  6. XIA Y, Dore V, Fripp J, Bourgeat P, et al
    Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease.
    Neurology. 2024;103:e209626.
    PubMed     Abstract available


  7. MASTENBROEK SE, Sala A, Vallez Garcia D, Shekari M, et al
    Continuous beta-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity.
    Neurology. 2024;103:e209419.
    PubMed     Abstract available


    June 2024
  8. DUBINSKY RM, Stein AC
    Predicting Driving Cessation in Alzheimer Disease: Performance Beats Biomarkers.
    Neurology. 2024;102:e209523.
    PubMed    


  9. BABULAL GM, Chen L, Murphy SA, Carr DB, et al
    Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments.
    Neurology. 2024;102:e209426.
    PubMed     Abstract available


  10. YE R, Goodheart AE, Locascio JJ, Peterec E, et al
    Differential Vulnerability of Hippocampal Subfields to Amyloid and Tau Deposition in the Lewy Body Diseases.
    Neurology. 2024;102:e209460.
    PubMed     Abstract available


  11. JADICK MF, Robinson T, Farrell ME, Klinger H, et al
    Associations Between Self and Study Partner Report of Cognitive Decline With Regional Tau in a Multicohort Study.
    Neurology. 2024;102:e209447.
    PubMed     Abstract available


  12. SUN M, He Q, Sun N, Han Q, et al
    Intrinsic Capacity, Polygenic Risk Score, APOE Genotype, and Risk of Dementia: A Prospective Cohort Study Based on the UK Biobank.
    Neurology. 2024;102:e209452.
    PubMed     Abstract available


  13. BOLSEWIG K, van Unnik AAJM, Blujdea ER, Gonzalez MC, et al
    Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
    Neurology. 2024;102:e209418.
    PubMed     Abstract available


    May 2024
  14. DITTRICH A, Westman E, Shams S, Skillback T, et al
    Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.
    Neurology. 2024;102:e209402.
    PubMed     Abstract available


  15. VASSILAKI M, Pittock RR, Aakre JA, Castillo AM, et al
    Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2024;102:e209377.
    PubMed    


  16. CHIABOTTI PS, Rouaud O, Allali G
    Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2024;102:e209375.
    PubMed    


  17. LEWIS A, Galetta S
    Editors' Note: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2024;102:e209376.
    PubMed    


  18. WOOD ALEXANDER M, Wu CY, Coughlan GT, Puri T, et al
    Associations Between Age at Menopause, Vascular Risk, and 3-Year Cognitive Change in the Canadian Longitudinal Study on Aging.
    Neurology. 2024;102:e209298.
    PubMed     Abstract available


  19. GRASSET L, Bouteloup V, Cacciamani F, Pellegrin I, et al
    Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort.
    Neurology. 2024;102:e209307.
    PubMed     Abstract available


    April 2024
  20. BUCKLEY RF, Schindler SE
    Lower Accuracy Alzheimer Disease Blood Tests Will Never Be "Ready for Prime Time".
    Neurology. 2024;102:e209295.
    PubMed    


  21. BOUTELOUP V, Pellegrin I, Dubois B, Chene G, et al
    Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia.
    Neurology. 2024;102:e209219.
    PubMed     Abstract available


  22. RAJAN KB, Mcaninch EA, Wilson RS, Dhana A, et al
    Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.
    Neurology. 2024;102:e209168.
    PubMed     Abstract available


  23. ASKEN BM, Tanner JA, Vandevrede L, Apple A, et al
    Linking Type and Extent of Head Trauma to Cavum Septum Pellucidum in Older Adults With and Without Alzheimer Disease and Related Dementias.
    Neurology. 2024;102:e209183.
    PubMed     Abstract available


  24. NELSON SE, Lopez OL
    Lecanemab for Alzheimer Disease: Is It Worth It?
    Neurology. 2024;102:e209265.
    PubMed    


  25. NADEAU SE
    Lecanemab Questions.
    Neurology. 2024;102:e209320.
    PubMed     Abstract available


  26. NGUYEN HV, Mital S, Knopman DS, Alexander GC, et al
    Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.
    Neurology. 2024;102:e209218.
    PubMed     Abstract available


  27. ALOSCO ML, Tartaglia MC
    Repetitive Blast Injury and CSF Alzheimer Disease Biomarkers: Navigating a Complex Narrative.
    Neurology. 2024;102:e209294.
    PubMed    


  28. LI G, Iliff J, Shofer J, Mayer CL, et al
    CSF beta-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury.
    Neurology. 2024;102:e209197.
    PubMed     Abstract available


  29. OVEISGHARAN S, Grodstein F, Evia AM Jr, James BD, et al
    Association of Age-Related Neuropathologic Findings at Autopsy With a Claims-Based Epilepsy Diagnosis in Older Adults.
    Neurology. 2024;102:e209172.
    PubMed     Abstract available


  30. WEINSTEIN G, Kojis DJ, Ghosh S, Beiser AS, et al
    Association of Neurotrophic Factors at Midlife With In Vivo Measures of beta-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults.
    Neurology. 2024;102:e209198.
    PubMed     Abstract available


  31. LU Y, Pike JR, Hoogeveen R, Walker K, et al
    Nonalcoholic Fatty Liver Disease and Longitudinal Change in Imaging and Plasma Biomarkers of Alzheimer Disease and Vascular Pathology.
    Neurology. 2024;102:e209203.
    PubMed     Abstract available


  32. BUCHMAN AS, Yu L, Klein HU, Zammit AR, et al
    Glycoproteome-Wide Discovery of Cortical Glycoproteins That May Provide Cognitive Resilience in Older Adults.
    Neurology. 2024;102:e209223.
    PubMed     Abstract available


  33. CAI Y, Shi D, Lan G, Chen L, et al
    Association of beta-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
    Neurology. 2024;102:e209205.
    PubMed     Abstract available


    March 2024
  34. HONIG M, Altomare D, Caprioglio C, Collij L, et al
    Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease.
    Neurology. 2024;102:e208053.
    PubMed     Abstract available


  35. ACKLEY S, Calmasini C, Bouteloup V, Hill-Jarrett TG, et al
    Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort.
    Neurology. 2024;102:e208054.
    PubMed     Abstract available


  36. GUO C, Harshfield EL, Markus HS
    Sleep Characteristics and Risk of Stroke and Dementia: An Observational and Mendelian Randomization Study.
    Neurology. 2024;102:e209141.
    PubMed     Abstract available


  37. FLEISHER AS, Munsie LM, Perahia DGS, Andersen SW, et al
    Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
    Neurology. 2024;102:e208061.
    PubMed     Abstract available


  38. CHRISTENSEN GM, Li Z, Liang D, Ebelt S, et al
    Association of PM(2.5) Exposure and Alzheimer Disease Pathology in Brain Bank Donors-Effect Modification by APOE Genotype.
    Neurology. 2024;102:e209162.
    PubMed     Abstract available


    February 2024
  39. HILL-JARRETT TG, Choi M, Buto PT, Miramontes S, et al
    Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing.
    Neurology. 2024;102:e208005.
    PubMed     Abstract available


  40. PASE MP, Himali JJ, Puerta R, Beiser AS, et al
    Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia.
    Neurology. 2024;102:e208075.
    PubMed     Abstract available


  41. YASAR S, Nidadavolu L
    Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention.
    Neurology. 2024;102:e209180.
    PubMed    


  42. ADESUYAN M, Jani YH, Alsugeir D, Howard R, et al
    Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study.
    Neurology. 2024;102:e209131.
    PubMed     Abstract available


  43. SHINOTOH H
    White Matter Neuroinflammation Matters in Early Alzheimer Disease.
    Neurology. 2024;102:e208090.
    PubMed    


  44. TARAWNEH R
    YKL-40 as a New Plasma Biomarker for Dementia Risk: Are We There Yet?
    Neurology. 2024;102:e209145.
    PubMed    


  45. HARDY J, Schott JM
    Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
    Neurology. 2024;102:e208096.
    PubMed     Abstract available


  46. LOOMIS SJ, Miller R, Castrillo-Viguera C, Umans K, et al
    Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
    Neurology. 2024;102:e207919.
    PubMed     Abstract available


  47. CHOLERTON B, Latimer CS, Crane PK, Corrada MM, et al
    Neuropathologic Burden and Dementia in Nonagenarians and Centenarians.
    Neurology. 2024;102:e208060.
    PubMed     Abstract available


  48. PARK SY, Setiawan VW, Crimmins EM, White LR, et al
    Racial and Ethnic Differences in the Population-Attributable Fractions of Alzheimer Disease and Related Dementias.
    Neurology. 2024;102:e208116.
    PubMed     Abstract available


  49. WANG Q, Schindler SE, Chen G, Mckay NS, et al
    Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.
    Neurology. 2024;102:e208013.
    PubMed     Abstract available


  50. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
    Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
    Neurology. 2024;102:e208033.
    PubMed     Abstract available


    January 2024
  51. CASTILHOS RM, Snitz BE
    Longitudinal Cognitive Decline in Alzheimer Disease Prevention Trials.
    Neurology. 2024;102:e208067.
    PubMed     Abstract available


  52. DUBBELMAN MA, Hendriksen HMA, Harrison JE, Vijverberg EGB, et al
    Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.
    Neurology. 2024;102:e207978.
    PubMed     Abstract available


  53. LOPEZ OL, Villemagne VL, Chang YF, Cohen AD, et al
    Association Between beta-Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia.
    Neurology. 2024;102:e207920.
    PubMed     Abstract available


  54. PEROSA V, Zanon Zotin MC, Schoemaker D, Sveikata L, et al
    Association Between Hippocampal Volumes and Cognition in Cerebral Amyloid Angiopathy.
    Neurology. 2024;102:e207854.
    PubMed     Abstract available


  55. ZANON ZOTIN MC, Makkinejad N, Schneider JA, Arfanakis K, et al
    Sensitivity and Specificity of the Boston Criteria Version 2.0 for the Diagnosis of Cerebral Amyloid Angiopathy in a Community-Based Sample.
    Neurology. 2024;102:e207940.
    PubMed     Abstract available


    December 2023
  56. HANSEEUW BJ, Jacobs HIL, Schultz AP, Buckley RF, et al
    Association of Pathologic and Volumetric Biomarker Changes With Cognitive Decline in Clinically Normal Adults.
    Neurology. 2023;101:e2533-e2544.
    PubMed     Abstract available


    November 2023
  57. ZHOU Z, Ryan J, Tonkin AM, Zoungas S, et al
    Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study.
    Neurology. 2023;101:e2288-e2299.
    PubMed     Abstract available


  58. YOON SH, Kim HK, Lee JH, Chun JH, et al
    Association of Sleep Disturbances With Brain Amyloid and Tau Burden, Cortical Atrophy, and Cognitive Dysfunction Across the AD Continuum.
    Neurology. 2023;101:e2162-e2171.
    PubMed     Abstract available


  59. FERGUSON EL, Zimmerman SC, Jiang C, Choi M, et al
    Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan.
    Neurology. 2023;101:e2172-e2184.
    PubMed     Abstract available


  60. NELSON PT, Jicha GA
    Early Hippocampal Atrophy Is an Important Signal for Clinicians, but Not Necessarily a Harbinger of Alzheimer Disease.
    Neurology. 2023 Nov 15:10.1212/WNL.0000000000208071.
    PubMed    


  61. PITTOCK RR, Aakre JA, Castillo AM, Ramanan VK, et al
    Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Neurology. 2023;101:e1837-e1849.
    PubMed     Abstract available


  62. HOWE MD, Rabinovici GD, Salloway SP
    Real-World Application of Anti-beta-Amyloid Monoclonal Antibodies: Untangling Eligibility.
    Neurology. 2023;101:811-812.
    PubMed    


    October 2023
  63. THEIS H, Bischof GN, Bruggemann N, Dargvainiene J, et al
    In Vivo Measurement of Tau Depositions in Anti-IgLON5 Disease Using (18)F-PI-2620 PET.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000207870.
    PubMed     Abstract available


  64. ALAM JJ, Maruff P, Doctrow SR, Chu HM, et al
    Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
    Neurology. 2023;101:e1708-e1717.
    PubMed     Abstract available


  65. SANTAMARIA BA, Corroza J, Sanchez-Ruiz de Gordoa J, Cabello C, et al
    Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease: A Potential Diagnostic Approach.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207865.
    PubMed     Abstract available


  66. STARK M, Wolfsgruber S, Kleineidam L, Frommann I, et al
    Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.
    Neurology. 2023 Oct 11:10.1212/WNL.0000000000207844.
    PubMed     Abstract available


  67. GONZALES MM, Vela G, Philip V, Trevino H, et al
    Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort.
    Neurology. 2023;101:e1531-e1541.
    PubMed     Abstract available


  68. OVEISGHARAN S, Yu L, Agrawal S, Nag S, et al
    Relation of Motor Impairments to Neuropathologic Changes of Limbic-Predominant Age-Related TDP-43 Encephalopathy in Older Adults.
    Neurology. 2023;101:e1542-e1553.
    PubMed     Abstract available


  69. BONOMI S, Samara A, Balestra N, Padalia A, et al
    Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-beta-Amyloid Monoclonal Antibody Treatment.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207927.
    PubMed    


  70. BRENNER S
    Reader Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:633-634.
    PubMed    


  71. OVEISGHARAN S, Bennett DA
    Author Response: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:634.
    PubMed    


  72. GANESH A, Galetta S
    Editors' Note: Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023;101:633.
    PubMed    


  73. LEWIS A, Gupta A, Oh I, Schindler SE, et al
    Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic.
    Neurology. 2023;101:e1424-e1433.
    PubMed     Abstract available


    September 2023
  74. GOODSMITH MS, Wroblewski KE, Schumm LP, McClintock MK, et al
    Association of APOE epsilon4 Status With Long-term Declines in Odor Sensitivity, Odor Identification, and Cognition in Older US Adults.
    Neurology. 2023;101:e1341-e1350.
    PubMed     Abstract available


  75. COOMANS EM, de Koning LA, Rikken RM, Verfaillie SC, et al
    Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207794.
    PubMed     Abstract available


  76. MALPETTI M, Rabinovici GD
    From Clinical Trials to Memory Clinics, tau-PET Visual Reads Can Help Diagnosis and Patient Stratification.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207935.
    PubMed    


  77. YAMAGUCHI S, Murakami T, Satoh M, Komiyama T, et al
    Associations of Dental Health With the Progression of Hippocampal Atrophy in Community-Dwelling Individuals: The Ohasama Study.
    Neurology. 2023;101:e1056-e1068.
    PubMed     Abstract available


    August 2023
  78. MONTEIRO C, Toth B, Brunstein F, Bobbala A, et al
    A Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants with Mild-to-Moderate Alzheimer's Disease (Lauriet).
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207663.
    PubMed     Abstract available


  79. EDLAND SD, Ucsd, Llibre-Guerra JJ
    Semorinemab in Mild to Moderate Alzheimer Disease: A Glimmer of Hope Though Cautions Remain.
    Neurology. 2023 Aug 29:10.1212/WNL.0000000000207861.
    PubMed    


  80. KAMAL F, Morrison C, Maranzano J, Zeighami Y, et al
    White Matter Hyperintensity Trajectories in Patients With Progressive and Stable Mild Cognitive Impairment.
    Neurology. 2023;101:e815-e824.
    PubMed     Abstract available


  81. PARNETTI L, Bellomo G
    Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
    Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
    PubMed    


  82. KAWADA T
    Reader Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:333-334.
    PubMed    


  83. PROSSER L
    Author Response: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:334.
    PubMed    


  84. LEWIS A, Galetta S
    Editors' Note: Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2023;101:333.
    PubMed    


  85. RAMANAN VK, Graff-Radford J, Syrjanen J, Shir D, et al
    Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort.
    Neurology. 2023 Aug 14:10.1212/WNL.0000000000207675.
    PubMed     Abstract available


  86. CATHARINA BOON BD, Labuzan S, Peng Z, Matchett B, et al
    Retrospective Evaluation of Neuropathologic Proxies of the Minimal Atrophy Subtype Compared to Corticolimbic Alzheimer Disease Subtypes.
    Neurology. 2023 Aug 14:10.1212/WNL.0000000000207685.
    PubMed     Abstract available


  87. LAM AD
    Linking Late-Onset Epilepsy With Alzheimer Disease: Insights From Plasma Amyloid Measurements.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207683.
    PubMed    


  88. JOHNSON EL, Sullivan KJ, Schneider ALC, Simino J, et al
    Association of Plasma Abeta 42/40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207635.
    PubMed     Abstract available


  89. HADDAD A, Brunel G, Indart S, Paquet C, et al
    A Patient With the Posterior Variant of Alzheimer Disease Plays Table Tennis: Blindsight and Pingpong.
    Neurology. 2023 Aug 3:10.1212/WNL.0000000000207650.
    PubMed    


    July 2023
  90. DURCAN R, Roberts G, Hamilton CA, Donaghy PC, et al
    Serial Nigrostriatal Dopaminergic Imaging in Mild Cognitive Impairment With Lewy Bodies, Alzheimer Disease, and Age-Matched Controls.
    Neurology. 2023 Jul 31:10.1212/WNL.0000000000207621.
    PubMed     Abstract available


  91. RAMANAN VK, Armstrong MJ, Choudhury P, Coerver K, et al
    Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology.
    Neurology. 2023 Jul 26:10.1212/WNL.0000000000207757.
    PubMed     Abstract available


  92. PROKOPIOU PC, Engels-Dominguez N, Schultz AP, Sepulcre J, et al
    Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease.
    Neurology. 2023 Jul 25:10.1212/WNL.0000000000207646.
    PubMed     Abstract available


  93. KARCESKI S, Antonopoulos M
    Biomarkers in Alzheimer Disease: A Review.
    Neurology. 2023;101:e461-e463.
    PubMed    


  94. ANDRE C, Kuhn E, Rehel S, Ourry V, et al
    Association of Sleep-Disordered Breathing and Medial Temporal Lobe Atrophy in Cognitively Unimpaired Amyloid-Positive Older Adults.
    Neurology. 2023;101:e370-e385.
    PubMed     Abstract available


  95. ALCOLEA D, Beeri MS, Rojas JC, Gardner RC, et al
    Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
    Neurology. 2023;101:172-180.
    PubMed     Abstract available


  96. BURKE JF, Richard S, Langa KM, Albin RL, et al
    Lecanemab: Looking Before We Leap.
    Neurology. 2023 Jul 21:10.1212/WNL.0000000000207505.
    PubMed     Abstract available


  97. SHIR D, Pham NTT, Botha H, Koga S, et al
    Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome.
    Neurology. 2023;101:e289-e299.
    PubMed     Abstract available


  98. DITTRICH A, Ashton NJ, Zetterberg H, Blennow K, et al
    Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg.
    Neurology. 2023;101:e277-e288.
    PubMed     Abstract available


  99. MOSER ED, Manemann SM, Larson NB, St Sauver JL, et al
    Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease Related Dementias.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207595.
    PubMed     Abstract available


  100. BARBA L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, et al
    CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease.
    Neurology. 2023;101:e50-e62.
    PubMed     Abstract available


  101. FERREIRA PCL, Ferrari-Souza JP, Tissot C, Bellaver B, et al
    Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials.
    Neurology. 2023;101:38-45.
    PubMed     Abstract available


  102. LICHTER DG, Hershey L
    Proposal to Add FDG-PET as an Outcome Measure for Clinical Trials in Patients With Prodromal Lewy Body Dementia.
    Neurology. 2023 Jul 3:10.1212/WNL.0000000000207498.
    PubMed    


    June 2023
  103. KNOPMAN DS, Hershey L
    Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift.
    Neurology. 2023 Jun 9:10.1212/WNL.0000000000207438.
    PubMed     Abstract available


    May 2023
  104. GROBER E, Petersen KK, Lipton RB, Hassenstab J, et al
    Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.
    Neurology. 2023;100:e2279-e2289.
    PubMed     Abstract available


  105. FANG Y, Si X, Wang J, Wang Z, et al
    Alzheimer Disease and Epilepsy: A Mendelian Randomization Study.
    Neurology. 2023 May 24:10.1212/WNL.0000000000207423.
    PubMed     Abstract available


  106. LUO J, Ma Y, Agboola FJ, Grant E, et al
    Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Lifespan.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207378.
    PubMed     Abstract available


  107. DIAZ-GALVAN P, Przybelski SA, Lesnick TG, Schwarz CG, et al
    beta-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies.
    Neurology. 2023 May 18:10.1212/WNL.0000000000207393.
    PubMed     Abstract available


  108. ALVES F, Kalinowski P, Ayton S
    Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs: A Systematic Review and Meta-analysis.
    Neurology. 2023;100:e2114-e2124.
    PubMed     Abstract available


  109. DU J, Li A, Shi D, Chen X, et al
    Association of APOE4, Osteoarthritis, beta-Amyloid, and Tau Accumulation in Primary Motor and Somatosensory Regions in Alzheimer Disease.
    Neurology. 2023 May 15:10.1212/WNL.0000000000207369.
    PubMed     Abstract available


  110. BUTLER PAGNOTTI RM, Pudumjee SB, Cross CL, Miller JB, et al
    Cognitive and Clinical Characteristics of Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy.
    Neurology. 2023;100:e2027-e2035.
    PubMed     Abstract available


  111. CICOGNOLA C, Mattsson-Carlgren N, van Westen D, Zetterberg H, et al
    Associations of CSF PDGFRbeta With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
    Neurology. 2023 May 3:10.1212/WNL.0000000000207358.
    PubMed     Abstract available


  112. SINHA N, Gugger JJ
    Towards a Patient-Specific Readout of Neurodegeneration: The Case for Spatial Normative Modeling in Alzheimer Disease.
    Neurology. 2023 May 1:10.1212/WNL.0000000000207280.
    PubMed    


  113. VERDI S, Kia SM, Yong KXX, Tosun D, et al
    Revealing Individual Neuroanatomical Heterogeneity in Alzheimer Disease Using Neuroanatomical Normative Modeling.
    Neurology. 2023 May 1:10.1212/WNL.0000000000207298.
    PubMed     Abstract available


    April 2023
  114. GERTJE EC, Janelidze S, van Westen D, Cullen N, et al
    Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
    Neurology. 2023;100:e1812-e1824.
    PubMed     Abstract available


  115. KUHN E, Perrotin A, La Joie R, Touron E, et al
    Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
    Neurology. 2023 Apr 21:10.1212/WNL.0000000000207338.
    PubMed     Abstract available


  116. INSEL PS, Kumar A, Hansson O, Mattsson-Carlgren N, et al
    Genetic Moderation of the Association of beta-Amyloid With Cognition and MRI in Alzheimer Disease.
    Neurology. 2023 Apr 21:10.1212/WNL.0000000000207305.
    PubMed     Abstract available


  117. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
    Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
    Neurology. 2023;100:e1691-e1701.
    PubMed     Abstract available


  118. YANG Z, Wei C, Li X, Yuan J, et al
    Association Between Regular Laxative Use and Incident Dementia in UK Biobank Participants.
    Neurology. 2023;100:e1702-e1711.
    PubMed     Abstract available


  119. TIAN J, Raghavan Pillai SK, Reid RI, Przybelski SA, et al
    White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease.
    Neurology. 2023 Apr 17:10.1212/WNL.0000000000207250.
    PubMed     Abstract available


  120. BRODTMANN A, Beversdorf DQ
    The Alzheimer Disconnectome.
    Neurology. 2023 Apr 17:10.1212/WNL.0000000000207303.
    PubMed    



  121. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-Amyloid Immunotherapy: A Meta-analysis.
    Neurology. 2023 Apr 4:10.1212/WNL.0000000000207344.
    PubMed    


  122. WANG Y, Liang J, Fang Y, Yao D, et al
    Burden of Common Neurologic Diseases in Asian Countries, 1990-2019: An Analysis for the Global Burden of Disease Study 2019.
    Neurology. 2023 Apr 4:10.1212/WNL.0000000000207218.
    PubMed     Abstract available


    March 2023
  123. BARKHOF F, Knopman DS
    Brain Shrinkage in Anti-beta-Amyloid Alzheimer Trials: Neurodegeneration or Pseudo-atrophy?
    Neurology. 2023 Mar 27:10.1212/WNL.0000000000207268.
    PubMed    


  124. ZHANG Y, Liu X, Wiggins KL, Kurniansyah N, et al
    Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts.
    Neurology. 2023 Mar 16:10.1212/WNL.0000000000207157.
    PubMed     Abstract available


  125. AGARWAL P, Leurgans SE, Agrawal S, Aggarwal N, et al
    Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology.
    Neurology. 2023 Mar 8:10.1212/WNL.0000000000207176.
    PubMed     Abstract available


  126. KURIHARA M, Komatsu H, Sengoku R, Shibukawa M, et al
    CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.
    Neurology. 2023;100:e1009-e1019.
    PubMed     Abstract available


  127. CHAPMAN S, Renteria MA, Dworkin JD, Garriga SM, et al
    Association of Subjective Cognitive Decline With Progression to Dementia in a Cognitively Unimpaired Multiracial Community Sample.
    Neurology. 2023;100:e1020-e1027.
    PubMed     Abstract available


    February 2023
  128. TIAN Q, An Y, Kitner-Triolo MH, Davatzikos C, et al
    Associations of Olfaction With Longitudinal Trajectories of Brain Volumes and Neuropsychological Function in Older Adults.
    Neurology. 2023;100:e964-e974.
    PubMed     Abstract available


  129. SARTO J, Ruiz-Garcia R, Guillen N, Ramos-Campoy O, et al
    Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
    Neurology. 2023;100:e860-e873.
    PubMed     Abstract available


  130. FERREIRA D, Przybelski SA, Lesnick TG, Schwarz CG, et al
    Cross-sectional Associations of beta-Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies.
    Neurology. 2023;100:e846-e859.
    PubMed     Abstract available


  131. MCCUSKER EA, Loy CT
    Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers.
    Neurology. 2023 Feb 15:10.1212/WNL.0000000000207199.
    PubMed    


  132. GECZI K
    Right Brain: Oriented to Self.
    Neurology. 2023;100:349-350.
    PubMed     Abstract available


    January 2023
  133. LARGENT EA, Grill J, O'Brien K, Wolk D, et al
    Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.
    Neurology. 2023 Jan 31:10.1212/WNL.0000000000206891.
    PubMed     Abstract available


  134. OVEISGHARAN S, Yang J, Yu L, Burba D, et al
    Estrogen Receptor Genes, Cognitive Decline, and Alzheimer Disease.
    Neurology. 2023 Jan 25:10.1212/WNL.0000000000206833.
    PubMed     Abstract available



  135. Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease.
    Neurology. 2023 Jan 24:10.1212/WNL.0000000000201690.
    PubMed    



  136. Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
    Neurology. 2023 Jan 23:10.1212/WNL.0000000000206876.
    PubMed    


  137. OHRFELT A, Benedet AL, Ashton NJ, Kvartsberg H, et al
    Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
    Neurology. 2023;100:e275-e285.
    PubMed     Abstract available


  138. ALTY JE, Bindoff AD, Stuart KE, Roccati E, et al
    Sex-Specific Protective Effects of Cognitive Reserve on Age-Related Cognitive Decline: A 5-Year Prospective Cohort Study.
    Neurology. 2023;100:e211-e219.
    PubMed     Abstract available


  139. SAJJADI SA, Bukhari S, Scambray KA, Yan R, et al
    Impact and Risk Factors of Limbic Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Change in an Oldest-Old Cohort.
    Neurology. 2023;100:e203-e210.
    PubMed     Abstract available


  140. GLANS I, Sonestedt E, Nagga K, Gustavsson AM, et al
    Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period.
    Neurology. 2023;100:e28-e37.
    PubMed     Abstract available


    December 2022
  141. BARRIO IR, Miki Y, Jaunmuktane ZT, Warner T, et al
    Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
    Neurology. 2022 Dec 16:10.1212/WNL.0000000000201659.
    PubMed     Abstract available


    November 2022
  142. RAJAN K, McAninch EA, Aggarwal N, Barnes LL, et al
    Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample.
    Neurology. 2022 Nov 29:10.1212/WNL.0000000000201289.
    PubMed     Abstract available


  143. HUANG J, Su B, Karhunen V, Gill D, et al
    Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization.
    Neurology. 2022 Nov 16. pii: WNL.0000000000201489.
    PubMed     Abstract available


  144. ROYALL DR
    Reader Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:918-919.
    PubMed    


  145. GANESH A, Galetta S
    Editors' Note: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:918.
    PubMed    


  146. QIU WQ, Tao Q, Akhter-Khan SC
    Author Response: Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous APOE varepsilon4 Carriers.
    Neurology. 2022;99:919.
    PubMed    


  147. YU L, Hsieh YC, Pearse RV, Wang Y, et al
    Association of AK4 Protein From Stem Cell-Derived Neurons With Cognitive Reserve: An Autopsy Study.
    Neurology. 2022;99:e2264-e2274.
    PubMed     Abstract available


  148. PROSSER L, MacDougall A, Sudre CH, Manning EN, et al
    Predicting Cognitive Decline in Nondemented Elders Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
    Neurology. 2022 Nov 10. pii: WNL.0000000000201572.
    PubMed     Abstract available


  149. ROSENBERG A, Ohlund-Wistbacka U, Hall A, Bonnard A, et al
    beta-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
    Neurology. 2022;99:e2102-e2113.
    PubMed     Abstract available


  150. TANGEN GG, Nilsson MH, Stomrud E, Palmqvist S, et al
    Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.
    Neurology. 2022;99:e2081-e2091.
    PubMed     Abstract available


  151. GHAHREMANI M, Wang M, Chen HY, Zetterberg H, et al
    Plasma P-Tau181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease.
    Neurology. 2022 Nov 2. pii: WNL.0000000000201517.
    PubMed     Abstract available


    October 2022
  152. MICHIELS L, Thijs L, Mertens N, Sunaert S, et al
    In Vivo Detection of Neurofibrillary Tangles by 18F-MK-6240 PET/MR in Patients With Ischemic Stroke.
    Neurology. 2022 Oct 27. pii: WNL.0000000000201344.
    PubMed     Abstract available


  153. SUCHY-DICEY AM, Oziel K, Sawyer C, Olufadi Y, et al
    Educational and Clinical Associations With Longitudinal Cognitive Function and Brain Imaging in American Indians: The Strong Heart Study.
    Neurology. 2022 Oct 26. pii: WNL.0000000000201261.
    PubMed     Abstract available


  154. QUISPIALAYA KM, Therriault J, Aliaga A, Zimmermann M, et al
    Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases.
    Neurology. 2022 Oct 20. pii: WNL.0000000000201198.
    PubMed     Abstract available


  155. PLANCHE V, Bouteloup V, Pellegrin I, Mangin JF, et al
    Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
    Neurology. 2022 Oct 19. pii: WNL.0000000000201479.
    PubMed     Abstract available


  156. GREENBERG BD, Pettigrew C, Soldan A, Wang J, et al
    CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and ApoE4.
    Neurology. 2022;99:e1640-e1650.
    PubMed     Abstract available


    September 2022

  157. Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
    Neurology. 2022 Sep 30. pii: WNL.0000000000201298.
    PubMed    


  158. GALE SA, Heidebrink J, Grill J, Graff-Radford J, et al
    Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.
    Neurology. 2022 Sep 30. pii: WNL.0000000000201347.
    PubMed     Abstract available


  159. BEVERSDORF DQ, Scharre DW
    The Dilemma of the Clinical Utility of Alzheimer Biomarker Evaluation in Everyday Clinical Practice: My Favorite PETs.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201478.
    PubMed    


  160. ROMERO JR, Pinheiro A, Aparicio HJ, DeCarli CS, et al
    MRI Visible Perivascular Spaces and Risk of Incident Dementia: The Framingham Heart Study.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201293.
    PubMed     Abstract available


  161. DEMNITZ-KING H, Gonneaud J, Klimecki OM, Chocat A, et al
    Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults.
    Neurology. 2022;99:e1422-e1431.
    PubMed     Abstract available


  162. SUGDEN K, Caspi A, Elliott ML, Bourassa KJ, et al
    Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia.
    Neurology. 2022;99:e1402-e1413.
    PubMed     Abstract available


  163. CONSTANT AB, Basavaraju R, France J, Honig LS, et al
    Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology.
    Neurology. 2022 Sep 19. pii: WNL.0000000000200947.
    PubMed     Abstract available


  164. KAMAGATA K, Andica C, Takabayashi K, Saito Y, et al
    Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.
    Neurology. 2022 Sep 19. pii: WNL.0000000000201300.
    PubMed     Abstract available


  165. HICKS AJ, Ponsford JL, Spitz G, Dore V, et al
    beta-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study.
    Neurology. 2022;99:e1131-e1141.
    PubMed     Abstract available


  166. ZETTERBERG H, Schott JM
    Objectifying Subjective Cognitive Decline: The Prognostic Role of Alzheimer Biomarkers.
    Neurology. 2022 Sep 2. pii: WNL.0000000000201172.
    PubMed    


    August 2022
  167. QUILICO COUSINS KA, Arezoumandan S, Shellikeri S, Ohm D, et al
    CSF Biomarkers of Alzheimer Disease in Patients With Concomitant alpha-Synuclein Pathology.
    Neurology. 2022 Aug 30. pii: WNL.0000000000201202.
    PubMed     Abstract available


  168. DUBBELMAN MA, Verrijp M, Terwee CB, Jutten RJ, et al
    Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness.
    Neurology. 2022;99:e954-e964.
    PubMed     Abstract available


  169. JEONG SY, Suh CH, Shim WH, Lim JS, et al
    Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-beta-amyloid Immunotherapy: A Meta-analysis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201019.
    PubMed     Abstract available


  170. SALMON DP, Smirnov DS, Coughlin DG, Hamilton JM, et al
    Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease.
    Neurology. 2022 Aug 26. pii: WNL.0000000000201068.
    PubMed     Abstract available


  171. ROSTAMZADEH A, Bohr L, Wagner M, Baethge C, et al
    Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-Analysis.
    Neurology. 2022 Aug 26. pii: WNL.0000000000201072.
    PubMed     Abstract available


  172. BILLETTE OV, Ziegler G, Aruci M, Schutze H, et al
    Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease.
    Neurology. 2022;99:e775-e788.
    PubMed     Abstract available


  173. JEONG SH, Cha J, Park M, Jung JH, et al
    Association of Enlarged Perivascular Spaces With Amyloid Burden and Cognitive Decline in Alzheimer Disease Continuum.
    Neurology. 2022 Aug 19. pii: WNL.0000000000200989.
    PubMed     Abstract available


  174. DUMURGIER J, Sabia S, Zetterberg H, Teunissen CE, et al
    A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
    Neurology. 2022;99:e669-e678.
    PubMed     Abstract available


  175. GILL D, Vujkovic M
    The Potential of Genetic Data for Prioritizing Drug Repurposing Efforts.
    Neurology. 2022;99:267-268.
    PubMed    


  176. CROTTY GF, Keavney JL, Alcalay RN, Marek K, et al
    Planning for Prevention of Parkinson Disease: Now Is the Time.
    Neurology. 2022;99.
    PubMed     Abstract available


  177. PIAZZA F, Caminiti SP, Zedde M, Presotto L, et al
    Association of Microglial Activation With Spontaneous ARIA-E and Cerebrospinal Fluid Levels of Anti-A Autoantibodies.
    Neurology. 2022 Aug 8. pii: WNL.0000000000200892.
    PubMed     Abstract available


  178. AKINCI M, Pena-Gomez C, Operto G, Fuentes-Julian S, et al
    Pre-pandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200948.
    PubMed     Abstract available


  179. CEDRES N, Ferreira D, Nemy M, Machado A, et al
    Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200930.
    PubMed     Abstract available


    July 2022
  180. SHAHIM P, Zetterberg H, Simren J, Ashton NJ, et al
    Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes.
    Neurology. 2022;99:e347-e354.
    PubMed     Abstract available


  181. SCHINDLER SE, Karikari TK, Ashton NJ, Henson RL, et al
    Effect of Race on Prediction of Brain Amyloidosis by Plasma Abeta42/Abeta40, Phosphorylated Tau, and Neurofilament Light.
    Neurology. 2022;99:e245-e257.
    PubMed     Abstract available


  182. BORLAND E, Edgar C, Stomrud E, Cullen N, et al
    Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.
    Neurology. 2022 Jul 14. pii: WNL.0000000000200817.
    PubMed     Abstract available


  183. WYNN M
    My First Patient With Alzheimer's.
    Neurology. 2022 Jul 14. pii: WNL.0000000000201087.
    PubMed    


  184. KEUSS SE, Coath W, Nicholas JM, Poole T, et al
    Associations of beta-Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort.
    Neurology. 2022;99:e129-e141.
    PubMed     Abstract available


    June 2022
  185. MONTINE TJ, Corrada MM, Kawas C, Bukhari S, et al
    Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old.
    Neurology. 2022 Jun 15. pii: WNL.0000000000200832.
    PubMed     Abstract available


  186. PETERSEN KK, Lipton RB, Grober E, Davatzikos C, et al
    Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data.
    Neurology. 2022;98:e2425-e2435.
    PubMed     Abstract available


  187. YANG JJ, Keohane LM, Pan X, Qu R, et al
    Association of Healthy Lifestyles with Risk of Alzheimer Disease and Related Dementias in Low-Income Black and White Americans.
    Neurology. 2022 Jun 13. pii: WNL.0000000000200774.
    PubMed     Abstract available


  188. TANG B, Wang Y, Jiang X, Thambisetty M, et al
    Genetic Variation in Targets of Anti-diabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.
    Neurology. 2022 Jun 2. pii: WNL.0000000000200771.
    PubMed     Abstract available


    May 2022
  189. KUMAR A, Janelidze S, Stomrud E, Palmqvist S, et al
    beta-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
    Neurology. 2022 May 31. pii: WNL.0000000000200605.
    PubMed     Abstract available


  190. DUMURGIER J, Sabia S, Zetterberg H, Teunissen C, et al
    Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.
    Neurology. 2022 May 26. pii: WNL.0000000000200735.
    PubMed     Abstract available


  191. MOHANTY R, Ferreira D, Frerich S, Muehlboeck JS, et al
    Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
    Neurology. 2022 May 24. pii: WNL.0000000000200573.
    PubMed     Abstract available


  192. MCGIRR A, Nathan S, Ghahremani M, Gill S, et al
    Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms.
    Neurology. 2022;98:e2132-e2139.
    PubMed     Abstract available


  193. XICOTA L, Gyorgy B, Grenier-Boley B, Lecoeur A, et al
    Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults.
    Neurology. 2022 May 23. pii: WNL.0000000000200544.
    PubMed     Abstract available


  194. TOLLER G, Cobigo Y, Ljubenkov PA, Appleby BS, et al
    Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia.
    Neurology. 2022 May 18. pii: WNL.0000000000200582.
    PubMed     Abstract available


  195. FARNSWORTH VON CEDERWALD B, Josefsson M, Wahlin A, Nyberg L, et al
    Association of Cardiovascular Risk Trajectory With Cognitive Decline and Incident Dementia.
    Neurology. 2022;98:e2013-e2022.
    PubMed     Abstract available


  196. LI Z, Heckman MG, Kanekiyo T, Martens YA, et al
    Clinicopathologic Factors Associated With Reversion to Normal Cognition in Patients With Mild Cognitive Impairment.
    Neurology. 2022;98:e2036-e2045.
    PubMed     Abstract available


  197. ASKEN BM, Tanner JA, VandeVrede L, Mantyh WG, et al
    Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Neurology. 2022 May 16. pii: WNL.0000000000200678.
    PubMed     Abstract available


  198. AGOSTA F, Filippi M
    Natural Speech Analysis: A Window Into Alzheimer Disease Phenotypes.
    Neurology. 2022 May 4. pii: WNL.0000000000200843.
    PubMed    


  199. BEYDOUN MA, Beydoun HA, Fanelli-Kuczmarski MT, Weiss J, et al
    Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults.
    Neurology. 2022 May 4. pii: WNL.0000000000200289.
    PubMed     Abstract available


    April 2022
  200. CHO S, Quilico Cousins KA, Shellikeri S, Ash S, et al
    Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology.
    Neurology. 2022 Apr 29. pii: WNL.0000000000200581.
    PubMed     Abstract available


  201. WHITWELL J, Martin PR, Graff-Radford J, Machulda M, et al
    Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200336.
    PubMed     Abstract available


  202. VOGEL JW, Tosun D
    Multiple Cortical to Striatal Accumulation Trajectories of beta-Amyloid: Do All Roads Lead to Rome?
    Neurology. 2022;98:695-696.
    PubMed    


  203. COLLIJ LE, Salvado G, Wottschel V, Mastenbroek SE, et al
    Spatial-Temporal Patterns of beta-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis.
    Neurology. 2022;98:e1692-e1703.
    PubMed     Abstract available


  204. BEAUDIN AE, McCreary CR, Mazerolle EL, Gee M, et al
    Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy.
    Neurology. 2022;98:e1716-e1728.
    PubMed     Abstract available


  205. ARANHA MR, Fortea J, Carmona-Iragui M
    Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease.
    Neurology. 2022 Apr 25. pii: WNL.0000000000200704.
    PubMed    


  206. FRANK B, Ally M, Tripodis Y, Puzo C, et al
    Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease.
    Neurology. 2022 Apr 20. pii: WNL.0000000000200304.
    PubMed     Abstract available


  207. BEAMAN C, Kozii K, Hilal S, Liu M, et al
    Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration.
    Neurology. 2022;98:e1605-e1616.
    PubMed     Abstract available


  208. DIFRANCESCO JC, Stanzani L
    Increased Brain Volume: A Novel Biomarker of Neurodegeneration?
    Neurology. 2022;98:649-650.
    PubMed    


  209. SIBLE IJ, Nation DA
    Visit-to-Visit Blood Pressure Variability and CSF Alzheimer Disease Biomarkers in Cognitively Unimpaired and Mildly Impaired Older Adults.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200302.
    PubMed     Abstract available


  210. GRAFF-RADFORD J, Josephs K
    Author Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:644.
    PubMed    


  211. DASHEIFF R
    Reader Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:643.
    PubMed    


  212. SIEGLER JE 3RD, Galetta S
    Editors' Note: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2022;98:643.
    PubMed    


  213. FARRELL ME, Papp KV, Buckley RF, Jacobs HIL, et al
    Association of Emerging beta-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.
    Neurology. 2022;98:e1512-e1524.
    PubMed     Abstract available


  214. TIDEMAN P, Stomrud E, Leuzy A, Mattsson-Carlgren N, et al
    Association of beta-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.
    Neurology. 2022;98:e1525-e1533.
    PubMed     Abstract available


  215. GAUTHREAUX KM, Teylan MA, Katsumata Y, Mock C, et al
    Limbic-Predominant Age-Related TDP-43 Encephalopathy: Medical and Pathologic Factors Associated With Comorbid Hippocampal Sclerosis.
    Neurology. 2022;98:e1422-e1433.
    PubMed     Abstract available


  216. GU Y, Kociolek A, Fernandez KK, Cosentino SA, et al
    Clinical Trajectories at the End of Life in Dementia Patients With Alzheimer Disease and Lewy Body Neuropathologic Changes.
    Neurology. 2022 Apr 4. pii: WNL.0000000000200259.
    PubMed     Abstract available


    March 2022
  217. GUAN Y, Ebrahimzadeh SA, Cheng CH, Chen W, et al
    Association of Diabetes and Hypertension With Brain Structural Integrity and Cognition in the Boston Puerto Rican Health Study Cohort.
    Neurology. 2022 Mar 30. pii: WNL.0000000000200120.
    PubMed     Abstract available


  218. ZAMMIT AR, Yu L, Petyuk V, Schneider JA, et al
    Cortical Proteins and Individual Differences in Cognitive Resilience in Older Adults.
    Neurology. 2022;98:e1304-e1314.
    PubMed     Abstract available


  219. SALINAS J, Beiser AS, Samra JK, O'Donnell A, et al
    Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline.
    Neurology. 2022;98:e1337-e1348.
    PubMed     Abstract available


  220. PETERSEN RC
    Detecting Alzheimer Disease Clinically: How Early Can We Go?
    Neurology. 2022 Mar 25. pii: WNL.0000000000200172.
    PubMed    


  221. VAN DE BEEK M, Ooms FAH, Ebenau JL, Barkhof F, et al
    Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies.
    Neurology. 2022;98:e1262-e1272.
    PubMed     Abstract available


  222. VAN LOENHOUD AC, Groot C, Bocancea DI, Barkhof F, et al
    Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200116.
    PubMed     Abstract available


  223. JOSEPHS KA, Weigand SD, Whitwell J
    Characterizing Amyloid Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
    Neurology. 2022 Mar 21. pii: WNL.0000000000200287.
    PubMed     Abstract available


  224. HESHMATOLLAH A, Fani L, Koudstaal PJ, Ghanbari M, et al
    Plasma Amyloid Beta, Total-Tau and Neurofilament Light Chain Levels and the Risk of Stroke: A Prospective Population-Based Study.
    Neurology. 2022 Mar 1. pii: WNL.0000000000200004.
    PubMed     Abstract available


    February 2022
  225. DAY GS, Scarmeas N, Dubinsky R, Coerver K, et al
    Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: Report of the AAN Guidelines Subcommittee.
    Neurology. 2022 Feb 23. pii: WNL.0000000000200176.
    PubMed     Abstract available


  226. GROBER E, Lipton RB, Sperling RA, Papp KV, et al
    Associations of Stages of Objective Memory Impairment (SOMI) with Amyloid PET and Structural MRI: The A4 Study.
    Neurology. 2022 Feb 23. pii: WNL.0000000000200046.
    PubMed     Abstract available


  227. MATTSSON-CARLGREN N, Grinberg LT, Boxer A, Ossenkoppele R, et al
    Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
    Neurology. 2022 Feb 16. pii: WNL.0000000000200040.
    PubMed     Abstract available


  228. CHU WT, Wang WE, Zaborszky L, Golde TE, et al
    Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract.
    Neurology. 2022;98:e700-e710.
    PubMed     Abstract available


  229. EBENAU JL, Pelkmans W, Verberk IMW, Verfaillie S, et al
    Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
    Neurology. 2022 Feb 2. pii: WNL.0000000000200035.
    PubMed     Abstract available


    January 2022
  230. BOWN CW, Carare RO, Schrag MS, Jefferson AL, et al
    Physiology and Clinical Relevance of Enlarged Perivascular Spaces in the Aging Brain.
    Neurology. 2022;98:107-117.
    PubMed     Abstract available


  231. WHITTINGTON MD, Campbell JD, Rind D, Fluetsch N, et al
    Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
    Neurology. 2022 Jan 12. pii: WNL.0000000000013314.
    PubMed     Abstract available


  232. BALLARINI T, Melo van Lent D, Wagner M
    Author Response: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:89-90.
    PubMed    


  233. GANESH A, Galetta S
    Editors' Note: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:88.
    PubMed    


  234. BRENNER SR
    Reader Response: Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age.
    Neurology. 2022;98:88-89.
    PubMed    


  235. DA SILVA SOYOMBO NK, Rocha EL, Xavier LB, Oliveira RA, et al
    Biomarkers for Differential Diagnosis Between Chronic Traumatic Encephalopathy and Alzheimer Disease: A Systematic Review.
    Neurology. 2022;98.
    PubMed     Abstract available


    December 2021
  236. YOO HS, Jeon S, Cavedo E, Ko M, et al
    Association of beta-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.
    Neurology. 2021 Dec 30. pii: WNL.0000000000013277.
    PubMed     Abstract available


  237. CULLEN N, Janelidze S, Palmqvist S, Stomrud E, et al
    Association of CSF Abeta38 Levels With Risk of Alzheimer Disease-Related Decline.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013228.
    PubMed     Abstract available


  238. YU L, Boyle PA, Wingo AP, Yang J, et al
    Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013252.
    PubMed     Abstract available


  239. LI Y, Schindler SE, Bollinger JG, Ovod V, et al
    Validation of Plasma Amyloid-beta 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
    Neurology. 2021 Dec 14. pii: WNL.0000000000013211.
    PubMed     Abstract available


    November 2021
  240. SMIRNOV DS, Salmon DP, Galasko D, Goodwill VS, et al
    Association of Neurofibrillary Tangle Distribution With Age at Onset-Related Clinical Heterogeneity in Alzheimer Disease: An Autopsy Study.
    Neurology. 2021 Nov 22. pii: WNL.0000000000013107.
    PubMed     Abstract available


  241. ACOSTA LM
    I Wasn't There: Caring for a Patient With Trisomy 21, Alzheimer Disease, and Epilepsy Until His Final Days With COVID-19.
    Neurology. 2021 Nov 22. pii: WNL.0000000000013109.
    PubMed     Abstract available


  242. CHIONG W, Tolchin BD, Bonnie RJ, Busl K, et al
    Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement.
    Neurology. 2021 Nov 17. pii: WNL.0000000000013053.
    PubMed    


  243. KUSCHPEL MS
    Reader Response: Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Neurology. 2021;97:964-965.
    PubMed    


  244. SCHELBAUM E, Loughlin L, Jett S, Zang C, et al
    Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife.
    Neurology. 2021 Nov 3. pii: WNL.0000000000012941.
    PubMed     Abstract available


    October 2021
  245. LEUZY A, Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al
    Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
    Neurology. 2021;97:e1681-e1694.
    PubMed     Abstract available


    September 2021
  246. KIM YJ, Karceski S
    Alzheimer Disease and Mood.
    Neurology. 2021;97:e1363-e1366.
    PubMed    


  247. EDMONDS EC, Smirnov DS, Thomas KR, Graves LV, et al
    Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.
    Neurology. 2021;97:e1288-e1299.
    PubMed     Abstract available


  248. MILA-ALOMA M, Brinkmalm A, Ashton NJ, Kvartsberg H, et al
    CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012853.
    PubMed     Abstract available


  249. GARNIER-CRUSSARD A, Krolak-Salmon P
    Reader Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;97:608.
    PubMed    


  250. THERRIAULT J, Pascoal T, Gauthier S, Rosa-Neto P, et al
    Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;97:609.
    PubMed    


  251. JEONG SH, Kim HR, Kim J, Kim H, et al
    Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment.
    Neurology. 2021;97:e1110-e1122.
    PubMed     Abstract available


  252. HERSHEY LA, Tarawneh R
    Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?
    Neurology. 2021;97:517-518.
    PubMed    


  253. SCHINDLER S, Li Y, Buckles VD, Gordon BA, et al
    Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012775.
    PubMed     Abstract available


  254. BUCIUC M, Josephs KA, Jones DT, Whitwell JL, et al
    Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012783.
    PubMed    


  255. MCCARTER S, Lesnick TG, Lowe V, Mielke MM, et al
    Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-beta PET Signal.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012770.
    PubMed     Abstract available


    August 2021
  256. FRISON E, Proust-Lima C, Mangin JF, Habert MO, et al
    Diabetes Mellitus and Cognition: Pathway Analysis in the MEMENTO Cohort.
    Neurology. 2021;97:e836-e848.
    PubMed     Abstract available


  257. SANDERS AE
    A Century-Old Problem: Cognition and Neuropsychiatric Symptoms in Alzheimer Disease.
    Neurology. 2021 Aug 20. pii: WNL.0000000000012616.
    PubMed    


  258. EIKELBOOM WS, van den Berg E, Singleton EH, Baart SJ, et al
    Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations.
    Neurology. 2021 Aug 19. pii: WNL.0000000000012598.
    PubMed     Abstract available


  259. LI J
    Alzheimer's Villanelle.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012612.
    PubMed    


  260. PETERSEN RC
    Mild Cognitive Impairment Criteria in Alzheimer's Disease Neuroimaging Initiative: Meeting Biological Expectations.
    Neurology. 2021 Aug 2. pii: WNL.0000000000012588.
    PubMed    


    July 2021
  261. TAO Q, Alvin Ang TF, Akhter-Khan SC, Itchapurapu IS, et al
    Impact of C-Reactive Protein on Cognition and Alzheimer Disease Biomarkers in Homozygous Apolipoprotein E varepsilon4 Carriers.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012512.
    PubMed     Abstract available


  262. BOCANCEA DI, Catharina van Loenhoud A, Groot C, Barkhof F, et al
    Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012499.
    PubMed     Abstract available


  263. GROTHE MJ, Moscoso A, Ashton NJ, Karikari TK, et al
    Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012513.
    PubMed     Abstract available


  264. POGGESI A
    Resilience and Resistance in Aging and Alzheimer Disease: Another Step to Fill the Gap Between Clinicians and Researchers.
    Neurology. 2021 Jul 15. pii: WNL.0000000000012500.
    PubMed    


  265. WILSON RS, Wang T, Yu L, Grodstein F, et al
    Cognitive Activity and Onset Age of Incident Alzheimer Disease Dementia.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012388.
    PubMed     Abstract available


  266. SALLOWAY S, Cummings J
    Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease.
    Neurology. 2021 Jul 7. pii: WNL.0000000000012451.
    PubMed    


    June 2021
  267. BUCIUC M, Duffy JR, Machulda MM, Graff-Radford J, et al
    Clinical, Imaging, and Pathologic Characteristics of Patients With Right Versus Left Hemisphere-Predominant Logopenic Progressive Aphasia.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012322.
    PubMed     Abstract available


  268. JUTTEN RJ, Sikkes SAM, Van der Flier WM, Scheltens P, et al
    Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.
    Neurology. 2021;96:e2673-e2684.
    PubMed     Abstract available


  269. BUCKLEY RF, Knopman DS
    Cognitive Heterogeneity in Alzheimer Clinical Trials: Harnessing Noise to Achieve Meaningfulness.
    Neurology. 2021;96:1017-1018.
    PubMed    


    May 2021
  270. HUGHES TM, Hajjar I
    Is Late-onset Alzheimer Disease Spelled "ATV(N)"?
    Neurology. 2021 May 24. pii: WNL.0000000000012259.
    PubMed    


  271. DONADIO V, Wang Z, Incensi A, Rizzo G, et al
    In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
    Neurology. 2021;96:e2513-e2524.
    PubMed     Abstract available


  272. FRIEDMAN LG, McKeehan N, Hara Y, Cummings JL, et al
    Value-Generating Exploratory Trials in Neurodegenerative Dementias.
    Neurology. 2021;96:944-954.
    PubMed     Abstract available


  273. MAYBLYUM DV, Becker JA, Jacobs HIL, Buckley RF, et al
    Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.
    Neurology. 2021 May 5. pii: WNL.0000000000012108.
    PubMed     Abstract available


  274. BALLARINI T, Melo van Lent D, Brunner J, Schroder A, et al
    Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age.
    Neurology. 2021 May 5. pii: WNL.0000000000012067.
    PubMed     Abstract available


  275. BELLAVER B, Ferrari-Souza JP, Uglione da Ros L, Carter SF, et al
    Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021 May 5. pii: WNL.0000000000012109.
    PubMed     Abstract available


  276. HAZRATI LN, Schwab N
    Embracing the Unknown in the Diagnosis of Traumatic Encephalopathy Syndrome.
    Neurology. 2021;96:835-836.
    PubMed    


    April 2021
  277. BOERWINKLE AH, Wisch JK, Chen CD, Gordon BA, et al
    Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012123.
    PubMed     Abstract available


  278. KARCESKI S
    The Effects of Long-term Medication Use in Alzheimer Disease.
    Neurology. 2021;96:e2247-e2250.
    PubMed    


  279. XU H, Garcia-Ptacek S, Jonsson L, Wimo A, et al
    Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Neurology. 2021;96:e2220-e2230.
    PubMed     Abstract available


  280. ROBERTS G, Durcan Mrcpi R, Donaghy PC, Lawley S, et al
    Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012060.
    PubMed     Abstract available


  281. HAMILTON CA, Matthews FE, Donaghy PC, Taylor JP, et al
    Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease.
    Neurology. 2021 Apr 19. pii: WNL.0000000000012024.
    PubMed     Abstract available


  282. HOWARD E, Irwin DJ, Rascovsky K, Nevler N, et al
    Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
    Neurology. 2021;96:e1855-e1864.
    PubMed     Abstract available


    March 2021
  283. QIAN J, Betensky RA, Hyman BT, Serrano-Pozo A, et al
    Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.
    Neurology. 2021 Mar 26. pii: WNL.0000000000011883.
    PubMed     Abstract available


  284. GOTTESMAN RF, Hamilton R
    Recruiting Diverse Populations in Clinical Trials: How Do We Overcome Selection Bias?
    Neurology. 2021;96:509-510.
    PubMed    


  285. KANG SH, Kim ME, Jang H, Kwon H, et al
    Amyloid Positivity in Alzheimer/Subcortical-Vascular Spectrum.
    Neurology. 2021 Mar 15. pii: WNL.0000000000011833.
    PubMed     Abstract available


  286. SMIRNOV DS, Galasko D, Hiniker A, Edland S, et al
    Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease.
    Neurology. 2021 Mar 15. pii: WNL.0000000000011772.
    PubMed     Abstract available


  287. BARKHOF BF, Pressman PS
    Time Is of the Essence: Early Detection of Incipient Alzheimer Pathology.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011739.
    PubMed    


    February 2021
  288. ROBINSON-PAPP J, Saylor D
    HIV in the Brain: From Devastating Dementia to White Matter Hyperintensities.
    Neurology. 2021 Feb 26. pii: WNL.0000000000011735.
    PubMed    


  289. HUYNH K, Piguet O, Kwok J, Dobson-Stone C, et al
    Clinical and Biological Correlates of White Matter Hyperintensities in Patients with Behavioral-variant Frontotemporal Dementia and Alzheimer Disease.
    Neurology. 2021 Feb 17. pii: WNL.0000000000011638.
    PubMed     Abstract available


  290. THERRIAULT J, Pascoal TA, Benedet AL, Tissot C, et al
    Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment.
    Neurology. 2021;96:e975-e985.
    PubMed     Abstract available


  291. RENTZ DM, Papp KV, Mayblyum DV, Sanchez JS, et al
    Association of Digital Clock Drawing with PET Amyloid and Tau Pathology in Normal Older Adults.
    Neurology. 2021 Feb 15. pii: WNL.0000000000011697.
    PubMed     Abstract available


  292. DETERS K, Napolioni V, Sperling RA, Greicius MD, et al
    Amyloid PET imaging in self-identified non-Hispanic Blacks from the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
    Neurology. 2021 Feb 10. pii: WNL.0000000000011599.
    PubMed     Abstract available


  293. FERREIRA D, Nordberg A, Westman E
    Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:238.
    PubMed    


  294. ULEMAN JF, Melis RJF, Olde Rikkert MGM
    Reader Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:237-238.
    PubMed    


  295. GANESH A, Galetta S
    Editors' Note: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis.
    Neurology. 2021;96:237.
    PubMed    


    January 2021
  296. JOSEPH-MATHURIN N, Wang G, Kantarci K, Jack CR Jr, et al
    Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease.
    Neurology. 2021 Jan 25. pii: WNL.0000000000011542.
    PubMed     Abstract available


  297. SAJJADI SA, Ash S, Cappa S
    Glass half full: Preservation of memory in Alzheimer-related primary progressive aphasia.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011404.
    PubMed    


  298. MESULAM MM, Coventry C, Kuang A, Bigio EH, et al
    Memory resilience in Alzheimer's disease with primary progressive aphasia.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011397.
    PubMed     Abstract available


  299. BLAZHENETS G, Frings L, Ma Y, Sorensen A, et al
    Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011521.
    PubMed     Abstract available


  300. JAGUST WJ, Landau SM
    Temporal Dynamics of Beta-amyloid Accumulation in Aging and Alzheimer's Disease.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011524.
    PubMed     Abstract available


  301. TRELLE AN, Carr VA, Wilson EN, Swarovski MS, et al
    Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease.
    Neurology. 2021 Jan 6. pii: WNL.0000000000011477.
    PubMed     Abstract available


  302. THERRIAULT J, Pascoal TA, Savard M, Benedet AL, et al
    Topographic Distribution of Amyloid-beta, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease.
    Neurology. 2021;96:e81-e92.
    PubMed     Abstract available


    December 2020
  303. KNOPMAN DS, Jagust WJ
    Alzheimer Disease Spectrum: Syndrome and Etiology from Clinical and PET Imaging Perspectives.
    Neurology. 2020 Dec 22. pii: WNL.0000000000011415.
    PubMed    


  304. KOYAMA AK, Irwin DJ
    Alzheimer disease biomarker profiles in dementia with Lewy bodies: Does A plus T spell D-L-B?
    Neurology. 2020;95:1076-1077.
    PubMed    


  305. GICAS KM, Honer WG, Wilson RS, Boyle PA, et al
    Association of serial position scores on memory tests and hippocampal-related neuropathologic outcomes.
    Neurology. 2020;95:e3303-e3312.
    PubMed     Abstract available


  306. PETTIGREW C, Soldan A, Wang J, Wang MC, et al
    Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline.
    Neurology. 2020;95:e3093-e3103.
    PubMed     Abstract available


  307. PALMQVIST S, Eshaghi A
    Spatial distribution of tau and beta-amyloid pathologies and their role in different Alzheimer's disease phenotypes.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011272.
    PubMed    


  308. LA JOIE R, Visani AV, Lesman-Segev OH, Baker SL, et al
    Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011270.
    PubMed     Abstract available


    November 2020
  309. KARCESKI S
    How a buildup of abnormal proteins in the brain may be the key to understanding Alzheimer disease.
    Neurology. 2020;95:e2951-e2953.
    PubMed    


  310. YOUNAN D, Wang X, Casanova R, Barnard R, et al
    PM2.5 associated with gray matter atrophy reflecting increased Alzheimers risk in older women.
    Neurology. 2020 Nov 18. pii: WNL.0000000000011149.
    PubMed     Abstract available


  311. ILLAN-GALA I, Lleo A, Karydas A, Staffaroni AM, et al
    Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease.
    Neurology. 2020 Nov 16. pii: WNL.0000000000011226.
    PubMed     Abstract available


  312. GRAFF-RADFORD J, Knopman D, Jones D
    Author response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:846.
    PubMed    


  313. ALLALI G, Laticevschi T
    Reader response: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:845-846.
    PubMed    


  314. SIEGLER JE 3RD, Galetta S
    Editors' note: Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition.
    Neurology. 2020;95:845.
    PubMed    


    October 2020
  315. KIM HR, Lee T, Choi JK, Jeong Y, et al
    Genetic variants beyond amyloid and tau associated with cognitive decline: A cohort study.
    Neurology. 2020;95:e2366-e2377.
    PubMed     Abstract available


  316. WEIGAND AJ, Bondi MW, Thomas KR, Campbell NL, et al
    Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.
    Neurology. 2020;95:e2295-e2304.
    PubMed     Abstract available


  317. KERCHNER GA, Filippi M
    Abeta-PET pathology accumulation index: Ready for the clinic?
    Neurology. 2020 Oct 19. pii: WNL.0000000000011060.
    PubMed    


  318. LEUZY A, Lilja J, Buckley CJ, Ossenkoppele R, et al
    Derivation and utility of an Abeta-PET pathology accumulation index to estimate Abeta load.
    Neurology. 2020 Oct 19. pii: WNL.0000000000011031.
    PubMed     Abstract available


  319. BENNETT DA, Knopman DS
    Extending Alzheimer disease biomarker studies into the Hispanic community.
    Neurology. 2020;95:665-666.
    PubMed    


  320. NAG S, Barnes LL, Yu L, Wilson RS, et al
    Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents.
    Neurology. 2020;95:e2056-e2064.
    PubMed     Abstract available


  321. GERTJE EC, van Westen D, Panizo C, Mattsson-Carlgren N, et al
    Association of enlarged perivascular spaces and measures of small vessel and Alzheimers disease.
    Neurology. 2020 Oct 12. pii: WNL.0000000000011046.
    PubMed    


  322. KAPASI A, Yu L, Boyle PA, Barnes LL, et al
    Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging.
    Neurology. 2020;95:e1951-e1962.
    PubMed     Abstract available


  323. CATRICALA E, Polito C, Presotto L, Esposito V, et al
    Neural correlates of naming errors across different neurodegenerative diseases: A FDG-PET study.
    Neurology. 2020 Oct 1. pii: WNL.0000000000010967.
    PubMed     Abstract available


    September 2020
  324. HANES J, Kovac A, Kvartsberg H, Kontsekova E, et al
    Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias.
    Neurology. 2020 Sep 24. pii: WNL.0000000000010814.
    PubMed     Abstract available


  325. BRENOWITZ WD, Besser LM, Kukull WA, Keene CD, et al
    Clinician-judged hearing impairment and associations with neuropathologic burden.
    Neurology. 2020;95:e1640-e1649.
    PubMed     Abstract available


  326. SCHREIBER S, DiFrancesco JC
    Impaired occipital cerebrovascular reactivity as a biomarker for vascular beta-amyloid.
    Neurology. 2020;95:415-416.
    PubMed    


  327. GUZMAN-VELEZ E, Martinez J, Papp K, Baena A, et al
    Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.
    Neurology. 2020;95:e1312-e1321.
    PubMed     Abstract available


    August 2020
  328. KIM JW, Byun MS, Lee JH, Yi D, et al
    Serum albumin and beta-amyloid deposition in the human brain.
    Neurology. 2020;95:e815-e826.
    PubMed     Abstract available


  329. VAN DER ZANDE JJ, Gouw AA, van Steenoven I, van de Beek M, et al
    Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies.
    Neurology. 2020;95:e662-e670.
    PubMed     Abstract available


    July 2020
  330. COLLIJ LE, Heeman F, Salvado G, Ingala S, et al
    Multi-tracer model for staging cortical amyloid deposition using PET imaging.
    Neurology. 2020 Jul 16. pii: WNL.0000000000010256.
    PubMed     Abstract available


  331. EBENAU JL, Timmers T, Wesselman LMP, Verberk IMW, et al
    ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
    Neurology. 2020;95:e46-e58.
    PubMed     Abstract available


  332. SAKAE N, Santos OA, Pedraza O, Litvan I, et al
    Clinical and pathologic features of cognitive-predominant corticobasal degeneration.
    Neurology. 2020;95:e35-e45.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.